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We present a comparative study on 124 patients with hematologic malignancies who had undergone
reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-
matched unrelated (MUD), or an HLA-haploidentical related (HAPLO) donor. The conditioning regimen, which
consisted of ﬂudarabine, melphalan or busulfan, and alemtuzumab was administered to patients with
lymphoid (n ¼ 62) or myeloid disease (n ¼ 62). Mycophenolate mofetil was used as prophylaxis for graft-
versus-host disease (GVHD), and 38, 58, and 33 patients received transplants from MRD, MUD, and HAPLO
donors, respectively. Only 2 patients experienced primary graft failure (GF) after melphalan-based regimen,
whereas 8 of the 17 patients who received a transplant from HAPLO donors experienced a primary GF after
busulfan-based regimen. The cumulative incidence of grade III to IV acute GVHD in engrafted patients who
had received transplants fromMRD, MUD, or HAPLO donors was 3%, 11%, and 27%, respectively, and the 2-year
overall survival (OS) rates were 51%, 22%, and 23%, respectively. According to multivariate analysis, trans-
plantation from either MUD or HAPLO donors compared with MRD were adverse factors that affected the OS
(P ¼ .006 and P ¼ .002, respectively). In conclusion, the reduced-intensity regimen that included ﬂudarabine,
busulfan, or melphalan and alemtuzumab using only mycophenolate mofetil as the GVHD prophylaxis
conferred favorable outcomes in the MRD group but lower survival rates in the MUD and HAPLO groups. The
busulfan-based regimen led to a high incidence of GF in the HAPLO group, suggesting the need for modiﬁ-
cation or intensiﬁcation of immunosuppression.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION immune reconstitution have been signiﬁcant obstacles to
With the development of nonmyeloablative and reduced-
intensity conditioning, allogeneic hematopoietic stem cell
transplantation (SCT) can be offered to older andmore inﬁrm
patients who have hematological malignancies and are at a
high risk of relapse under conventional chemotherapy [1,2].
Our group and others previously showed that facilitation of
engraftment and reduced incidence of graft-versus-host
disease (GVHD) and treatment-related mortality (TRM)
were achieved in allogeneic SCT from HLA-matched sibling
donor or unrelated donor by using alemtuzumab: a hu-
manized monoclonal antibody directed against human CD52
that is expressed on many T and B cells and some dendritic
and NK cells [3-6]. We expanded this strategy further to
include haploidentical SCT [7]. The combined use of alem-
tuzumab (100 mg), ﬂudarabine, and cyclophosphamide as a
conditioning of haploidentical transplantation resulted in
low cumulative incidence of acute GVHD, low TRM, and an
acceptable incidence of primary graft failure (GF). However,
the high incidences of infection and relapse due to slowdgments on page 263.
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In the present prospective study, we reduced the dose of
alemtuzumab from 100 mg to 80 mg and replaced cyclo-
phosphamide with either busulfan or melphalan for myeloid
and lymphoid malignancies, respectively, to decrease inci-
dence of infectious complications and increase antitumor
activity in reduced-intensity peripheral blood stem cell
transplantation from HLA-matched related (MRD), HLA-
matched unrelated (MUD), and HLA-haploidentical related
(HAPLO) donors.METHODS
Patient and Donor Selection
The patient inclusion criteria were as follows: (1) patients at least
18 years of age; (2) patients not considered candidates for myeloablative
allogeneic SCT as a result of having other comorbidities, known recent
Aspergillus infection, advanced age, or prior high-dose therapy; (3) patients
who have pulmonary function test with single-breath diffusing capacity at
least 40% of the predicted value, cardiac ejection fraction at least 40%, and
Eastern Cooperative Oncology Group performance status of 2 or less; and (4)
fulﬁllment of the disease status described below. For the lymphoid cohort,
the target patient population exhibited a high likelihood for progressive
lymphoid or myelomatous disease: (1) acute lymphoid leukemia with no
more than 3 hematological remissions, (2) relapsed Hodgkin or non-
Hodgkin lymphoma that are chemosensitive to salvage chemotherapy, and
(3) myeloma or myelomatous disease that had persisted or progressed after
the use of at least 1 regimen. For the myeloid cohort, the target patient
population exhibited a high likelihood of progressive myeloid disease orTransplantation.
Table 1
Patient Characteristics
Characteristics MRD MUD HAPLO P
Value
No. of patients 38 53 33
Age, median
(range), yr
57 (20-69) 59 (22-73) 55 (23-70) .10
Sex
Female 20 (53%) 22 (42%) 12 (36%) .36
Male 18 (47%) 31 (58%) 21 (64%)
Diagnosis
Lymphoid
disease
21 (55%) 25 (47%) 16 (48%)
ALL 2 1 2
CLL 3 4 5
ML 13 18 9
MM 3 2 0 .73
Myeloid disease 17 (45%) 28 (53%) 17 (52%)
AML/MDS 17 25 14
CML 0 2 1
MPD 0 1 2
Disease status
Standard 28 (74%) 36 (68%) 23 (70%) .84
High 10 (26%) 17 (32%) 10 (30%)
HLA matching,
A,B,DR
3/6 - - 21 (64%)
4/6 - - 9 (27%) -
5/6 - - 3 (9%)
6/6 38 (100%) 53 (100%) -
KPS
<90 18 (47%) 23 (43%) 12 (36%)
90-100 20 (53%) 30 (57%) 20 (61%) .48
Missing 0 0 1 (3%)
HCT-CI
0 10 (26%) 8 (15%) 8 (24%)
1-2 9 (24%) 13 (25%) 3 (9%) .27
>3 19 (50%) 32 (60%) 22 (67%)
Prior history of
autologous
transplantation
Yes 6 (16%) 10 (19%) 3 (9%) .47
No 32 (84%) 43 (81%) 30 (91%)
CD34þ cells/kg,
 106, median
(range)
13.1 (1.9-25.5) 7.9 (2.7-21.0) 10.9 (1.8-20.8) <.01
Follow-up duration
among survivors,
median (range),
mo
28.6 (3.4-44.8) 23.7 (2.7-40.0) 26.3 (4.6-38.9) .67
KPS indicates Karnofsky Performance Status; HCT-CI, hematopoietic cell
transplantation-comorbidity index; MRD, HLA-matched related donor;
MUD, HLA-matched unrelated donor; HAPLO, HLA-haploidentical related
donor; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic
leukemia; ML, malignant lymphoma; MM, multiple myeloma; AML, acute
myelogenous leukemia; MDS, myelodysplastic syndrome; CML, chronic
myelogenous leukemia; MPD, myeloproliferative disease.
Data presented are n (%) unless otherwise indicated.
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3 hematological remissions, (2) myelodysplastic syndrome (MDS) with a
history of at least intermediate-1 risk according to the International Prog-
nostic Scoring System criteria, and (3) MPD.
The donor selection algorithm included a 5/6 to 6/6 matched sibling as
the ﬁrst choice, an available matched unrelated donor as the second choice,
or a 3/6 to 5/6 partially matched family member (if 5/6, the donor is not a
sibling, which would be ﬁrst choice) as the third choice. The protocol was
approved by the institutional review board of the Duke University School of
Medicine. Written informed consent was obtained from all patients and
donors. This protocol was registered at ClinicalTrials.gov (NCT00597714).
Treatment Plan
The conditioning regimen used for myeloid disease consisted of
ﬂudarabine (40 mg/m2/day) infused over a period of 30 minutes on days 5
through 2; busulfan (130 mg/m2/day) infused over a period of 3 hours on
days 3 through 2; and alemtuzumab (20 mg/day) infused over a period
of 3 hours on days 4 through 1. The conditioning regimen used for
lymphoid diseases consisted of ﬂudarabine (40 mg/m2/day) infused over a
period of 30 minutes on days 5 through 2; melphalan (140 mg/m2/day)
infused over a period of 15 minutes on day 2; and alemtuzumab (20 mg/
day) infused over a period of 3 hours on days -4 through -1. Peripheral blood
stem cells were mobilized from related or unrelated donors. The target goals
for related or unrelated donor harvest were 15 to 20  106 and 5  106
CD34þ cells/kg, respectively. GVHD prophylaxis consisted of mycophenolate
mofetil (1000 mg) administered orally or intravenously twice daily begin-
ning on day -2 and continuing until day þ60 post transplantation. Gran-
ulocyte colony-stimulating factor was not used routinely, except in patients
who showed no signs of hematopoietic recovery. Of patients who had
received transplants from MRD, 3 received subsequent unmanipulated
donor lymphocyte infusion (DLI) and 14 received NK celleenriched DLI in-
fusions. Of patients who received transplants fromMUD,1 received DLI, and
of patients who had received transplants fromHAPLO donors, 2 received DLI
and 2 received NK celleenriched DLI infusions. T/NK DLIs were mostly given
as planned on other post-transplantation protocols, except for 1 given for
mixed chimerism and another for relapsed disease.
Assessment of Engraftment and Toxicity
Bone marrow aspiration and/or biopsy were performed 3 to 5 weeks
after transplantation to assess donor-cell engraftment or determine the
cause for delayed neutrophil recovery. Samples of bone marrow or periph-
eral blood were used to assess donor cell chimerism. Recipient and donor
chimerism was determined by PCR ampliﬁcation and subsequent size
comparison of multiple short tandem repeats. Primary GF was deﬁned as a
neutrophil count below 500/mL or the absence of donor-derived hemato-
poiesis (<5% donor cells) before relapse, death, or retransplantation [8].
Secondary GFwas deﬁned as the achievement of primary engraftment and a
subsequent decrease in neutrophils to 3 consecutive counts of less than
100/mL or the absence of donor-derived hematopoiesis (<5% donor cells)
before relapse, death, or retransplantation. Neutrophil engraftment was
deﬁned as the achievement of a neutrophil count of at least 500/mL on or
before day 50 post transplantation. Acute or chronic GVHD was diagnosed
and graded according to standard criteria [9,10]. Toxicity was formally
graded using the National Cancer Institute Common Toxicity Criteria
(version 3.0; http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/docs/ctcaev3.pdf).
Measurement of Immune Recovery
Quantiﬁcation of CD3þ, CD4þ, and CD8þ T cells was performed by ﬂow
cytometry on fresh peripheral blood at approximately 1 month before
transplantation and then 1.5, 3, 6, and 12 months after transplantation.
Statistical Analysis
Descriptive statistics were used for summarizing variables related to
patient demographics and transplantation characteristics. Comparisons
among the groups were performed by use of the chi-square statistic for
categorical variables and the Kruskal-Wallis test for continuous variables.
The median  standard error values of the percentages were used to
describe the donor cell chimerism for the CD15þ and CD3þ cells of the bone
marrow or peripheral blood. These chimerism data were available in 34 and
35 patients of the lymphoid and myeloid cohorts, respectively. Disease-free
survival (DFS), progression-free survival (PFS), and overall survival (OS) rates
after SCT were estimated using the Kaplan-Meier method. We performed
univariate comparisons by using the log-rank test. DFS was deﬁned as the
period of time between the day of transplantation and either disease relapse
or death due to the disease; DFS was measured in all patients who, based on
all measureable criteria, had attained a complete response after trans-
plantation. PFS was deﬁned as the period of time between the day oftransplantation and either the day underlying disease progression was
documented or death occurred by any cause. OSwas deﬁned as the period of
time between the day of transplantation and death. To eliminate the effects
of competing risk, we assessed cumulative incidence by methods described
elsewhere [11], and we conducted univariate comparisons using the Gray
test. For the analysis of relapse and acute and chronic GVHD, we deﬁned a
competing event as death without an event of interest. For the analysis of
TRM, relapse was deﬁned as a competing risk. Acute GVHD was analyzed
among the patients who achieved and maintained donor cell engraftment,
and chronic GVHD was analyzed among the patients who achieved and
maintained donor cell engraftment and survived more than 100 days. Cox
proportional hazards regression was used to evaluate variables that poten-
tially affected DFS, PFS, and OS. The following variables were considered as
confounders: recipient age, recipient sex, disease (myeloid or lymphoid),
disease risk (standard or high), and donor type (MRD, MUD, or HAPLO
donor). The following were deﬁned as standard-risk diseases: acute leuke-
mia in complete remission (CR), chronic myelogenous leukemia in the
chronic phase, non-Hodgkin and Hodgkin lymphoma in CR, MDS or MPD in
CR or untreated, and multiple myeloma in CR. Other diseases were deﬁned
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Student t-test. The immune recovery rates of the CD3þ, CD4þ, and CD8þ
T cells in the MRD, MUD, and HAPLO groups were compared by performing
an analysis of variance at each time point after transplantation. All tests
were 2 sided and a P value less than .05 indicated statistical signiﬁcance. All
statistical analyses were performed using Stata version 12 (Stata Corp.;
College Station, TX, USA).
RESULTS
Patients and Graft Characteristics
A total of 124 patients with a median follow-up of
26 months (among surviving patients) were included in this
study (Table 1). The lymphoid cohort included 62 patients
who had acute lymphoid leukemia (n ¼ 5), chronic lym-
phocytic leukemia (n¼ 12), lymphoma (n ¼ 40), or myeloma
(n ¼ 5). The myeloid cohort included 62 patients with acute
myelogenous leukemia/MDS (n ¼ 56), chronic myelogenous
leukemia (n ¼ 3), or MPD (n ¼ 3). Median ages of MRD
(n ¼ 38), MUD (n ¼ 53), and HAPLO donors (n ¼ 33) were 57
(range, 20 to 69), 59 (range, 22 to 73), and 55 (range, 23 to
70), respectively. The CD34 counts of peripheral blood stem
cells for MRD, MUD, and HAPLO donors were 13.1  106/kg
(range, 1.9 to 25.5  107/kg), 7.9  106/kg (range, 2.7 to
21.0 107/kg), and 10.9 106/kg (range,1.8 to 20.8 107/kg),
respectively.
Engraftment
For the lymphoid cohort, all 21 patients who had received
a SCT from aMRD engrafted successfully, whereas 1 of the 25
patients who had received a SCT from a MUD experienced
secondary GF with complete donor chimerism that did not
respond to CD34-selected DLI. Among the 16 HAPLO pa-
tients, 2 exhibited primary GF; both underwent retrans-
plantation from the same donor and 1 was rescued. The
chimerism analysis at 1 month after SCT showed a meanFigure 1. Cumulative incidence of acute and chronic GVHD. Black line shows HLA-ma
and gray line shows HLA-haploidentical related donor (HAPLO).donor chimerism of 94.4%  2.6% for the CD15þ cells and
88.9%  3.0% for the CD3 þ cells. In the myeloid cohort, 1 of
the 17 patients who had received a transplant from a MRD
experienced a primary GF, which was caused by cytomega-
lovirus (CMV) reactivation most likely, and was rescued by
retransplantation from the same donor. Of the 28 patients
who had received a SCT from MUD, 2 experienced a primary
GF and 4 experienced a secondary GF. Four were rescued by a
subsequent SCT from the same MUD or a new HAPLO donor.
Eight of the 17 patients who had received transplants from
HAPLO donors experienced primary GF; 3 of the 8 under-
went retransplantation from the same or another HAPLO
donor, and 1 of the 8 received an autologous trans-
plantationdall 4 of these patients were rescued. One of the
remaining 4 patients received a DLI and a CD34 boost, but the
graft failed. One patient experienced secondary GF. The
chimerism analysis at 1 month after SCT showed a mean
donor chimerism of 91.6%  3.2% for CD15þ cells and
69.7%  6.0% for CD3 þ cells. We used the combination of
ﬂudarabine, cyclophosphamide, and alemtuzumab as a
salvage-conditioning regimen for GF in most cases [12]. We
also analyzed chimerism data at 1 month after SCT for both
malignancies focusing on the MUD and HAPLO group. A
mean donor chimerism of patients with and without
engraftment was 96.3%  1.0% and 78.6%  12.5% (P ¼ .003)
for CD15þ cells and 89.6%  3.2% and 39.6%  16.4%
(P< .001) for CD3þ cells. The median time period in days for
neutrophil engraftment after MRD, MUD, or HAPLO trans-
plantation was 19 (range, 13 to 27), 19 (range, 11 to 29), and
16.5 (range, 13 to 22) (P ¼ .06), respectively.GVHD
Among the engrafted patients who had received a
transplant from a MRD, MUD, or HAPLO donor, thetched related donor (MRD), dotted line shows HLA-matched unrelated donor,
Table 2
Infections According to Donor Type
Toxicity MRD MUD HAPLO Total
CMV reactivation 24 (63%) 26 (49%) 18 (55%) 68 (55%)
CMV disease 2 (5%) 6 (11%) 3 (9%) 11 (9%)
Bacteria 12 (32%) 22 (42%) 13 (39%) 47 (38%)
Clostridium difﬁcile 3 (8%) 4 (8%) 1 (3%) 8 (6%)
EB virus 1 (3%) 0 0 1 (1%)
HSV 3 (8%) 3 (6%) 7 (21%) 13 (10%)
VZV 1 (3%) 6 (11%) 1 (3%) 8 (6%)
HHV-6 1 (3%) 12 (23%) 11 (33%) 24 (19%)
AFB 2 (5%) 1 (2%) 0 3 (2%)
Polyoma virus 6 (16%) 15 (28%) 10 (30%) 31 (25%)
RS virus 3 (8%) 3 (6%) 2 (6%) 8 (6%)
Parainﬂuenza 4 (11%) 2 (4%) 3 (9%) 9 (7%)
Fungus 1 (3%) 5 (9%) 5 (15%) 11 (9%)
Aspergillus 1 (3%) 4 (8%) 0 5 (4%)
Candida species 0 0 1 (3%) 1 (1%)
Other fungus 0 1 (2%) 4 (12%) 6 (5%)
MRD indicates HLA-matched related donor; MUD, HLA-matched unrelated
donor; HAPLO, HLA-haploidentical related donor; CMV, cytomegalovirus;
EB, Epstein-Barr; HSV, herpes simplex virus; VZV, varicella zoster virus;
HHV-6, human herpesvirus 6; AFB, acid-fast bacilli.
Data presented are n (%).
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180 post transplantation was 16% (95% conﬁdence interval
[CI], 7% to 30%), 26% (95% CI, 14% to 39%), and 46% (95% CI,
24% to 65%), respectively (Gray test, P ¼ .044); and the cu-
mulative incidence of grades III to IV acute GVHD on day 180
was 3% (95% CI, 0.2 to 12%), 13% (95% CI, 5% to 25%), and 27%
(95% CI, 11% to 47%), respectively (Gray test, P ¼ .016)
(Figure 1). Among the engrafted patients who survived more
than 100 days, the incidence of chronic GVHD 2 years after
transplantation from MRD, MUD, or HAPLO donors was 22%
(95% CI, 9% to 37%), 35% (95% CI, 20% to 51%), and 39% (95% CI,
17% to 61%), respectively (Gray test, P ¼ .166) (Figure 1).Infections
Table 2 shows the incidence of infection (Grades  2
according to National Cancer Institute Common Toxicity
Criteria) according to donor type. In total, 55% of patients
experienced CMV reactivation and 9% developed CMV dis-
ease. Other infectious complications included polyoma virus
in 25% of patients, bacteria in 38%, Herpes simplex virus in
10%, varicella zoster virus in 6%, human herpesvirus 6 in 19%,
respiratory syncytial and parainﬂuenza viruses in 13%, and
fungi in 9%. The incidences of polyoma virus, fungal, and
human herpesvirus 6 infection were low in the MRD group,
whereas those of Herpes simplex virus and fungal infection
were high in the HAPLO group.Figure 2. Probability of disease-free survival, progression-free survival, and
overall survival. Black line shows HLA-matched related donor (MRD), dottedDFS, PFS, and OS
The 2-year DFS rate after SCT from MRD, MUD, and
HAPLO donors was 47% (95% CI, 29% to 63%), 23% (95% CI, 12%
to 36%), and 16% (95% CI, 5% to 33%), respectively (log-rank
test, P ¼ .021); the 2-year PFS rate was 43% (95% CI, 26% to
59%), 22% (95% CI, 11% to 34%), and 15% (95% CI, 5% to 30%),
respectively (log-rank test, P ¼ .042); and the corresponding
2-year OS rate was 51% (33% to 66%), 22% (12% to 35%), and
23% (10% to 39%), respectively (log-rank test, P ¼ .004)
(Figure 2). Multivariate analysis revealed that SCT fromMUD
or HAPLO donors in comparison to MRD was the only
adverse factor that affected the OS rate (hazard ratio [HR] for
MUD, 2.23 [95% CI, 1.26 to 3.93], P¼ .006; HR for HAPLO, 2.63
[1.42 to 4.87], P ¼ .002) (Table 3). However, the OS rate afterline shows HLA-matched unrelated donor, and gray line shows HLA-hap-
loidentical related donor (HAPLO).
Table 3
Multivariate Analysis of Factors Potentially Affecting Overall Survival
Variables HR (95% CI) P Value
Age (by 1 year) 1.01 (.99-1.03) .212
Sex
Male 1.00
Female 1.20 (.77-1.87) .419
Diagnosis
Myeloid disease 1.00
Lymphoid disease .85 (.53-1.38) .523
Disease risk
Standard 1.00
High 1.28 (.79-2.10) .317
Donor type
MRD 1.00
MUD 2.23 (1.26-3.93) .006
HAPLO 2.63 (1.42-4.87) .002
MRD indicates HLA-matched related donor; MUD, HLA-matched unrelated
donor; HAPLO, HLA-haploidentical related donor; CI, conﬁdence interval;
HR, hazard ratio.
Figure 3. Cumulative incidence of relapse and nonrelapse mortality. Black line
shows HLA-matched related donor (MRD), dotted line shows HLA-matched
unrelated donor, and gray line shows HLA-haploidentical related donor
(HAPLO).
Table 4
Causes of Death According to Donor Type
Cause of Death MRD
(n ¼ 38)
MUD
(n ¼ 53)
HAPLO
(n ¼ 33)
Total
Progressive disease 5 (28%) 13 (33%) 5 (19%) 23 (27%)
Infections 10 (56%) 15 (38%) 8 (31%) 33 (39%)
Rejection 0 0 3 (12%) 3 (4%)
GVHD 0 2 (5%) 3 (12%) 5 (6%)
Organ failure 0 2 (5%) 3 (12%) 5 (6%)
PTLD 1 (6%) 0 1 (4%) 2 (2%)
Others 1 (6%) 3 (8%) 1 (4%) 5 (6%)
Undetermined 1 (6%) 5 (13%) 2 (8%) 8 (10%)
MRD indicates HLA-matched related donor; MUD, HLA-matched unrelated
donor; HAPLO, HLA-haploidentical related donor; GVHD, graft-versus-host
disease; PTLD, post-transplantation lymphoproliferative disorder.
Data presented are n (%).
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OS rate after SCT from MUD (P ¼ .520). Other variables
(recipient age, sex, disease, and disease risk) were not
signiﬁcantly associated with the outcome.
Relapse and TRM
No signiﬁcant differences in relapse incidence occurred
among recipients who received SCT from MRD, MSD, or
HAPLO donors (Gray test, P ¼ .776). The relapse incidence
2 years after SCT was 28% (95% CI, 14 to 44%) for MRD, 28%
(16 to 42%) for MUD, and 24% (10% to 41%) for HAPLO donors
(Figure 3). On the other hand, nonrelapse mortality after SCT
was signiﬁcantly higher among recipients who received SCTs
from MUD and HAPLO donors (Gray test, P ¼ .018). The
nonrelapse mortality 2 years after SCT was 29% (95% CI, 15%
to 45%) for MRD, 50% (35% to 64%) for MUD, and 61% (41% to
76%) for HAPLO transplantation (Figure 3). The most com-
mon causes of death were progressive disease (27% of death
by all causes) and infection (39%) (Table 4).
Immune Recovery
The immune recovery data for the CD3þ, CD4þ, and
CD8þ T cells are shown in Figure 4. The number of these T
cells was very low at 1.5 months after transplantation and
then gradually recovered through 12 months after trans-
plantation. Although the median values of these T cells were
lower in the MUD and HAPLO groups than in the MRD group,
no signiﬁcant difference was found among the 3 groups.
DISCUSSION
There has been no standard conditioning regimen for
nonmyeloablative or reduced-intensity transplantation,
particularly from a HAPLO donor. Use of ex vivo CD34 se-
lection or T cell depletion methods decrease incidence of
severe acute GVHD, but render patients at high risk of
infection and relapse, as well as graft failure. Therefore, we
expanded our previous study of nonmyeloablative trans-
plantation using ﬂudarabine, melphalan or busulfan, a lower
dose of alemtuzumab, and only mycophenolate mofetil as a
GVHD prophylaxis. In this protocol, we observed favorable
outcomes for the MRD group either in the myeloid or
lymphoid cohort. However, high incidence GF in the myeloid
cohort of the MUD and HAPLO groups was observed after
busulfan-based regimen. This suggests that the use of
busulfan and ﬂudarabine in combination with alemtuzumabdoes not ensure donor engraftment, which indicates the
need for additional immunosuppression. Further, the most
common causes of death remain the same as our previous
Figure 4. Immune recovery of the (A) CD3þ, (B) CD4þ, and (C) CD8þ T cells. The median values before transplantation and 1.5, 3, 6, and 12 months after
transplantation are shown with the standard error bars. Black line shows HLA-matched related donor (MRD), dotted line shows HLA-matched unrelated donor, and
gray line shows HLA-haploidentical related donor (HAPLO).
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reduced the dose of alemtuzumab and used mycophenolate
mofetil as a single GVHD prophylaxis agent without in-
creasing the occurrence of severe acute GVHD, the reduction
in the alemtuzumab dose from 100 mg to 80 mg may be
inadequate for reducing infection and relapse rates and
actually did not improve T cell recovery in comparison with
our previous study [7]. Chakraverty et al. [4] tested a
reduced-intensity conditioning regimen with dose de-
escalated alemtuzumab after HLA-identical sibling SCT us-
ing cyclosporine as GVHD prophylaxis. They reported that a
20-mg dose of alemtuzumab was associated with a greater
risk of severe GVHD. In contrast, the 30-mg dose was asso-
ciated with comparable clinical outcomes and improved
lymphocyte recovery compared to the 40- or 60-mg dose
groups that had acceptable levels of severe GVHD incidence.
This study suggests that the alemtuzumab dose can be
reduced to 30 mg on day -1 before transplantation from an
HLA-identical sibling if cyclosporine is used as the single
GVHD prophylactic agent. Therefore, the dose of alemtuzu-
mab may be reduced to 30 mg after the MRD transplantation
under a less intensiﬁed post-transplantation GVHD prophy-
laxis. If a conventional GVHD prophylaxis, such as calcineurin
inhibitors with methotrexate or mycophenolate mofetil is
used, the dose of alemtuzumab may be further reduced, or
the administration may be discontinued, at least after the
MRD transplantation. However, because we observed an
incidence of grade III to IV acute GVHD in 27% after
HAPLO transplantation, the dose of alemtuzumab should be
reduced moderately, perhaps to 60 mg or less, for HAPLO
transplantation.
A high incidence of GF was noted in the myeloid cohort,
who were conditioned with a ﬂudarabine, busulfan, and
alemtuzumab regimen and who received mycophenolate
mofetil as GVHD prophylaxis. The chimerism analysis
showed a lower donor chimerism of CD3 þ cells in the
busulfan-based regimen than in the melphalan-based
regimen (69.7% versus 88.9%). Further, low donor chime-
rism of CD3 þ cells was associated with graft failure. This
ﬁnding suggests that these combinations were inadequate
for the suppression of recipient T cells. We previously re-
ported a high incidence of GF after single unrelated cord
blood transplantations that used a conditioning regimen ofﬂudarabine and busulfan (16 mg/kg) [13]. Based on these
ﬁndings, the combined use of ﬂudarabine and busulfan
inadequately ensures successful donor cell engraftment
particularly after cord or haploidentical transplantation. In
our previous study using ﬂudarabine, cyclophosphamide,
and alemtuzumab (100 mg), primary GF was seen in only 6%
of recipients after HAPLO transplantation [7]. The addition of
an alkylating agent (eg, melphalan or cyclophosphamide)
instead of busulfan and/or the addition of 2 to 4 Gy total body
irradiation will be needed to ensure engraftment following
transplantation from a MUD and HAPLO donor. In addition,
donor-speciﬁc HLA antibodies should be screened to further
decrease the risk of GF after HAPLO transplantation [14,15].
Relatively low doses of CD34 cells in the MUD group
compared with theMRD groupmay have affected the GF rate
of the MUD group. However, it is practically difﬁcult to
collect more CD34 cells from unrelated donors to ensure
donor cell engraftment. Another strategy to enhance donor
cell engraftment is increased intensity of GVHD prophylaxis.
Ogawa et al. [16] reported a high incidence of donor cell
engraftment after treatment with ﬂudarabine, busulfan, and
anti T-lymphocyte globulin, as well as GVHD prophylaxis that
consisted of tacrolimus and methylprednisolone. However,
because the high incidence of infection remains a problem in
the protocol, these prophylaxes may not improve the OS rate.
Although the high GF rate was observed in the myeloid
cohort, disease itself (myeloid versus lymphoid disease) was
not associated with other outcomes, such as acute and
chronic GVHD, relapse, TRM, and OS in the multivariate
analysis (data not shown). This suggests that choice of donor
source rather than treatment regimen had a strong effect on
other outcomes.
Recently, the use of post-transplantation cyclophospha-
mide was demonstrated to be effective for reducing the
incidence of severe acute GVHD and TRM in haploidentical
transplantation [17,18]. Brunstein et al. [18] performed a
phase II trial of haploidentical transplantation using post-
transplantation cyclophosphamide and reported 1-year
cumulative incidence rates of 7% and 45% for nonrelapse
mortality and relapse, respectively. The overall and PFS rates
at 1 year were 62% and 48%, respectively. Bashey et al. [19]
retrospectively compared the outcomes of HAPLO
transplantation with the use of post-transplantation
J. Kanda et al. / Biol Blood Marrow Transplant 20 (2014) 257e263 263cyclophosphamide and MRD and MUD transplantations.
They reported comparative results among the MRD, MUD,
and HAPLO groups. Compared with their approach, our
approach resulted in higher rates of TRM for the MUD and
HAPLO groups and higher rates of severe acute GVHD for the
HAPLO group, although the relapse rate was relatively lower.
The higher TRM in the MUD and HAPLO groups was partly
due to the high GF rates after the busulfan-based regimen,
the GVHD-associated complications, and delay in the im-
mune recovery after transplantation. These results suggest
that effective GVHD suppression without inhibiting graft-
versus-leukemia effects or delaying immune recovery re-
mains a major issue in our approach. We need an enhanced
strategy to boost immune recovery without increasing the
risk of severe GVHD and TRM by reducing the dose of
alemtuzumab, using additional immunosuppression with
cyclophosphamide or other agents, and discontinuation of
the use of busulfan as a conditioning regimen in this
approach. However, the results of this study should be
cautiously interpreted because of the relatively small sample
size and heterogeneity of the underlying diseases.
In conclusion, the reduced-intensity regimen that in-
cluded ﬂudarabine, busulfan or melphalan, and alemtuzu-
mab (80mg), using only mycophenolate mofetil as the GVHD
prophylaxis, conferred favorable outcomes in the MRD group
but lower survival rates in the MUD and HAPLO groups. The
busulfan-based regimen led to a high incidence of GF in the
MUD and HAPLO groups, suggesting the need for modiﬁca-
tion or intensiﬁcation of immunosuppression of the condi-
tioning regimen. The high incidences of disease recurrence
and infection suggest that the development of strategies to
improve immune recovery remains a challenge.
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